Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market

Corvus Pharmaceuticals Inc. (CRVS) announced an update on their ongoing clinical study.

The Phase 1 study titled “A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis” tests Corvus Pharmaceuticals, Inc.’s oral drug in patients with difficult eczema. It aims to show if the drug is safe and offers early signs of benefit, which could open a new market in a large chronic skin disease.

The trial evaluates soquelitinib, also known as CPI-818, an oral ITK inhibitor designed to adjust immune activity that drives atopic dermatitis. A placebo tablet is used as a control to compare safety and early efficacy signals against standard inactive treatment.

This is an interventional Phase 1 trial with patients randomly assigned to receive either soquelitinib or placebo. It uses a stepwise dose-escalation and expansion design with full blinding for patients, doctors, site staff, and outcome assessors, and the main goal is to assess treatment safety while looking for early signs of clinical improvement.

In the dose-escalation phase, patients received soquelitinib tablets at 100 mg twice daily, 200 mg once daily, or 200 mg twice daily for 28 days, or matching placebo. In the dose-expansion phase, participants received the selected soquelitinib dose or placebo for 56 days to build a broader view of tolerability and consistency of response.

The study was first submitted on March 12, 2024, marking the formal start of regulatory tracking and investor visibility. The trial is now listed as completed, with the most recent update posted on March 10, 2026, signaling that Corvus has finished dosing and follow-up and is likely analyzing data for potential release.

For investors, the completion of this early trial is a key milestone, as it can reduce some development risk if safety and early activity look favorable. Positive news could boost CRVS by strengthening its dermatology and immunology story, while weak or unclear results may weigh on sentiment in a market already watching leaders like Sanofi, Regeneron, and AbbVie in atopic dermatitis.

Given the size of the eczema market and ongoing demand for new oral options, any hint of clean safety and meaningful symptom relief would likely be viewed as a strategic upside for Corvus and could invite new partnerships or financing. At the same time, competition from established biologics and JAK inhibitors means investors should wait for clarity on both effect size and tolerability before adjusting long term expectations.

This Corvus Pharmaceuticals, Inc. study of soquelitinib in moderate to severe atopic dermatitis is now completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about CRVS’s potential, visit the Corvus Pharmaceuticals Inc. drug pipeline page.